$ARDS is delivering advancements in infection cont
Post# of 40256
(Total Views: 97)
Posted On: 06/15/2021 1:03:56 PM
$ARDS is delivering advancements in infection control. Review details here:
CRISPR Gene Editing Technology from MIT and Harvard Phase 3: Aridis Pharmaceuticals
June 10, 2021
Click here:
https://www.einpresswire.com/article/54343111...asdaq-ards
About Aridis Pharmaceuticals, Inc (NASDAQ ARDS).
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality.
CRISPR Gene Editing Technology from MIT and Harvard Phase 3: Aridis Pharmaceuticals
June 10, 2021
Click here:
https://www.einpresswire.com/article/54343111...asdaq-ards
About Aridis Pharmaceuticals, Inc (NASDAQ ARDS).
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality.
(0)
(0)Scroll down for more posts ▼